> you can Google up the figures easily enough

Is that right? I just keep hearing that there is some conspiracy trying to obscure the data, I figured it would be unavailable.

https://pubmed.ncbi.nlm.nih.gov/34865500/

We report on 139 adolescents and young adults with 140 episodes of suspected myocarditis (49 confirmed, 91 probable) at 26 centers. ... Twenty-six patients (18.7%) were in the intensive care unit, 2 were treated with inotropic/vasoactive support, and none required extracorporeal membrane oxygenation or died. Median hospital stay was 2 days (range, 0-10; IQR, 2-3).

Of 97 patients who underwent cardiac MRI at a median 5 days (range, 0-88; IQR, 3-17) from symptom onset, 75 (77.3%) had abnormal findings: 74 (76.3%) had late gadolinium enhancement, 54 (55.7%) had myocardial edema, and 49 (50.5%) met Lake Louise criteria. Among 26 patients with left ventricular ejection fraction <55% on echocardiogram, all with follow-up had normalized function (n=25).

https://jamanetwork.com/journals/jama/fullarticle/2788346

Approximately 96% of persons (784/813) were hospitalized and 87% (577/661) of these had resolution of presenting symptoms by hospital discharge. The most common treatment was nonsteroidal anti-inflammatory drugs (589/676; 87%).

https://pubmed.ncbi.nlm.nih.gov/34734240/

All cases occurred within 2 weeks of a dose of the COVID-19 mRNA vaccine with the majority occurring within 3 days (range 1-13 days) following the second dose (6/7 patients, 86%). Overall, cases were mild, and all patients survived.

COVID-19 Vaccination-Associated Myocarditis in Adolescents: https://pubmed.ncbi.nlm.nih.gov/34389692/

None of the patients required inotropic, mechanical, or circulatory support. There were no deaths. Follow-up data obtained in 86% of patients at a mean of 35 days revealed resolution of symptoms, arrhythmias, and ventricular dysfunction.

From the paper you linked to:

"""
Median hospital length of stay was 2 days (range 1-4 days) with no intensive care unit admission and no significant morbidity or mortality. All patients had resolution of chest pain and down-trending serum troponin level before discharge.

Follow-up cardiac MRI LVEF (57.7 ± 2.8%) was significantly improved from initial (54.5 ± 5.5%, P < .05), and none of the patients had regional wall motion abnormalities. LVEF by echocardiogram was normal for all patients at the time of follow-up.
"""

Though to be fair -- because I think there are too many shills on both sides of this topic -- it also notes:

"""
Notably, in our cohort, although there was significant reduction in LGE at follow-up, abnormal strain persisted for the majority of patients at follow-up.
"""

So thank you for prompting me to delve a little more into the outcomes of the vaccine-associated myocarditis cases. I feel even more reassured than before -- the cases seem to be exceedingly rare, even in the highest risk demographic. For anyone outside that highest-risk demographic, the risk of COVID-related myocarditis is higher than vaccine-related. When this exceedingly rare complication occurs, the majority of cases result in a brief hospitalization during which they are treated with ibuprofen.

I think it will be interesting to see how the risks of having COVID a second time compare with the risks of vaccination. I think it's fully possible that the immunity from prior infection could drastically reduce the risks of disease and shift the balance, but until this is better understood, it seems that the risks of vaccination seem to be extremely low -- even lower than the risks of COVID, even for the lowest risk demographics.